The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Managing immunotherapy-related toxicity in colorectal cancer
Jennifer Rachel Eads, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses strategies to overcome adverse events related to immunotherapy in patients with colorectal cancer. Whilst immunotherapy is less cytotoxic than most chemotherapies, side effects can still be severe. Steroids are typically administered to manage adverse events, with the aim rechallenge in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
